Longitudinal ctDNA has been confirmed with a relationship to clinical response or survival in melanoma, colorectal cancer (CRC), and gastric cancer patients with anti-PD-1 treatment.252–254 ctDNA carries and transmits tumour burden and genetic mutation information which can help clinicians screen more susceptible populations to ICB drugs. The gene discussed is PDCD1; the disease is melanoma.